{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-056375","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.753239+00:00","generated_at":"2026-06-28T09:08:03.088050+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kintara names Robert Hoffman as CEO; Saiid Zarrabian transitions to Head of Strategic Partnerships","bullets":["Robert E. Hoffman appointed President and CEO effective Nov 8, 2021; previously Chairman.","Saiid Zarrabian steps down as CEO, becomes Head of Strategic Partnerships.","Hoffman receives $551k base salary, 3,519,170 stock option grant (4-yr vest), target bonus up to 50%.","Zarrabian's new salary $285k, target bonus up to 40%; unvested options now tied to milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-056375","json":"https://secwatch.observer/filing/0001564590-21-056375.json","markdown":"https://secwatch.observer/filing/0001564590-21-056375.md","text":"https://secwatch.observer/filing/0001564590-21-056375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000156459021056375/0001564590-21-056375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000156459021056375/ktra-8k_20211108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:08:03.088050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06db10a328","claim":"Robert E. Hoffman was appointed as President and Chief Executive Officer at TuHURA Biosciences, Inc./NV.","evidence_excerpt":"On November 8, 2021, the Board of Directors (the “Board”) of Kintara Therapeutics, Inc. (the “Company”) appointed Robert E. Hoffman, the then current Chairman of the Board, to succeed Saiid Zarrabian as President and Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000156459021056375/0001564590-21-056375-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"47203753d2","claim":"Saiid Zarrabian changed role as Head of Strategic Partnerships at TuHURA Biosciences, Inc./NV.","evidence_excerpt":"on November 8, 2021, the Board and Mr. Zarrabian mutually agreed that Mr. Zarrabian would immediately transition into the role of Head of Strategic Partnerships.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1498382/000156459021056375/0001564590-21-056375-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Head of Strategic Partnerships"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}